We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


SCYNEXIS Receives Merial Research Collaboration Milestone Payment

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "SCYNEXIS Receives Merial Research Collaboration Milestone Payment"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:
Merial Limited and SCYNEXIS, Inc. have announced that SCYNEXIS has earned a fourth payment for meeting certain milestones in a multi-year research collaboration which began in 2005.

SCYNEXIS, a premier drug discovery and development company, directs considerable medicinal chemistry, advanced biological screening, bioanalytical and ADMET activities towards Merial's animal health discovery efforts.

"SCYNEXIS is pleased to earn another important research milestone through our valued partnership with Merial," said SCYNEXIS President and Chief Executive Officer Dr. Yves Ribeill. "This is the fourth consecutive milestone we have reached for delivering significant, innovative animal health development candidates to Merial under the agreement."

"Merial is delighted to see this latest success resulting from our pharmaceutical discovery collaboration with SCYNEXIS. This exciting addition to Merial's pharmaceutical pipeline shows what can be achieved when the best outside skills and resources are combined with Merial's in-house knowledge and expertise," said Dr. Christian Miculka, Head Discovery & Research.